Literature DB >> 2452607

Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1.

P J Venables1, T Pawlowski, P A Mumford, C Brown, D H Crawford, R N Maini.   

Abstract

Antibodies to rheumatoid arthritis nuclear antigen (RANA) are detected by immunodiffusion (ID) and immunofluorescence (IF), though reports of the identity of the antigen(s) have been conflicting. In this study it is shown conclusively that ID and IF anti-RANA react with epitopes on Epstein-Barr nuclear antigen 1 (EBNA-1) and that the major epitope detected by immunofluorescence is represented by a synthetic peptide, P62, corresponding to part of EBNA-1. In an enzyme linked immunosorbent assay (ELISA) anti-P62 antibodies in 35 rheumatoid arthritis sera were threefold higher than those of 35 age and sex matched controls, with the highest levels occurring in young patients with active joint disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452607      PMCID: PMC1003506          DOI: 10.1136/ard.47.4.270

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Antibodies to La, Jo-1, nRNP and Sm detected by multi-track immunoblotting using a novel filter holder: a comparative study with counterimmunoelectrophoresis and immunodiffusion using sera from patients with systemic lupus erythematosus and Sjögren's syndrome.

Authors:  D G Williams; M R Stocks; P J Charles; R N Maini
Journal:  J Immunol Methods       Date:  1986-07-11       Impact factor: 2.303

2.  Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis.

Authors:  T B Sculley; P J Walker; D J Moss; J H Pope
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

Review 3.  Unraveling the structure of the intermediate filaments.

Authors:  E Fuchs; I Hanukoglu
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

4.  Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen.

Authors:  I Ernberg; B Kallin; J Dillner; K Falk; B Ehlin-Henriksson; M L Hammarskjöld; G Klein
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

5.  Antibody to the rheumatoid arthritis nuclear antigen. Its relationship to in vivo Epstein-Barr virus infection.

Authors:  M A Catalano; D A Carson; J C Niederman; P Feorino; J H Vaughan
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

6.  Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen.

Authors:  G Rhodes; D A Carson; J Valbracht; R Houghten; J H Vaughan
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

7.  Correlation between the presence of antibodies to the Epstein-Barr virus nuclear antigen type 2 and antibodies to the rheumatoid arthritis nuclear antigen in patients with rheumatoid arthritis.

Authors:  T B Sculley; J H Pope; R A Hazelton
Journal:  Arthritis Rheum       Date:  1986-08

8.  A search for rheumatoid arthritis-associated nuclear antigen and Epstein-Barr virus specific antigens or genomes in tissues and cells from patients with rheumatoid arthritis.

Authors:  M A Alspaugh; H Shoji; M Nonoyama
Journal:  Arthritis Rheum       Date:  1983-06

9.  Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis.

Authors:  P K Kataaha; S M Mortazavi-Milani; G Russell; E J Holborow
Journal:  Ann Rheum Dis       Date:  1985-07       Impact factor: 19.103

10.  Titers of antibodies to RANA in rheumatoid arthritis and normal sera. Relationship to Epstein-Barr virus infection.

Authors:  P J Venables; L M Roffe; C C Erhardt; R N Maini; J M Edwards; A D Porter
Journal:  Arthritis Rheum       Date:  1981-12
View more
  9 in total

1.  Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology.

Authors:  M Gorgievski-Hrisoho; W Hinderer; H Nebel-Schickel; J Horn; R Vornhagen; H H Sonneborn; H Wolf; G Siegl
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

2.  Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes.

Authors:  R Misra; P J Venables; C Plater-Zyberk; P F Watkins; R N Maini
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

Review 3.  Epstein-Barr virus infection and autoimmunity in rheumatoid arthritis.

Authors:  P Venables
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

Review 4.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

Review 5.  Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis.

Authors:  R M Nakamura
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

6.  Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of Epstein-Barr nuclear antigen-1.

Authors:  C Baboonian; D Halliday; P J Venables; T Pawlowski; G Millman; R N Maini
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

7.  Evidence for monoclonal expansion of synovial T cells bearing V alpha 2.1/V beta 5.5 gene segments and recognizing a synthetic peptide that shares homology with a number of putative autoantigens.

Authors:  B Ostenstad; A Dybwad; T Lea; O Førre; O Vinje; M Sioud
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

Review 8.  Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands-Relation to Rheumatoid Arthritis.

Authors:  Nicole Trier; Jose Izarzugaza; Anna Chailyan; Paolo Marcatili; Gunnar Houen
Journal:  Int J Mol Sci       Date:  2018-01-21       Impact factor: 5.923

Review 9.  Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.

Authors:  Eng M Tan; Josef S Smolen
Journal:  J Exp Med       Date:  2016-09-12       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.